ISPE Releases its Drug Shortages Prevention Plan

News
Article

The International Society for Pharmaceutical Engineering (ISPE) released its Drug Shortages Prevention Plan as part of an initiative to address drug shortage prevention due to manufacturing and quality issues.

In response to the growing problem of drug shortages, the International Society for Pharmaceutical Engineering (ISPE) has released its Drug Shortages Prevention Plan. The plan, based on ISPE’s 2013 ISPE Drug Shortages Survey, presents industry with a plan to prevent drug shortages. The plan was created in a collective effort by industry experts and regulatory agencies in the US and Europe.

In the plan, ISPE suggests that companies investigate root causes for drug shortages and create a quality culture to ensure a reliable supply of drugs. The plan lays out a holistic approach for identifying root causes of drug shortages on technical, quality systems, and management levels. An emphasis on quality is expressed in chapters on cross-function and cross-level cooperation, third-party quality oversight, and process- and production-related root causes.

A discussion on quality metrics is also provided including sections on supply-chain practices. The plan also details the role regulatory agencies play in preventing drug shortages and how industry can work with regulators to ensure a robust supply of medicines.

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Related Content